Toxicological Reviews

, Volume 22, Issue 3, pp 165–190

The Role of Oximes in the Management of Organophosphorus Pesticide Poisoning

Review Article

Abstract

The number of intoxications with organophosphorus pesticides (OPs) is estimated at some 3 000 000 per year, and the number of deaths and casualties some 300 000 per year. OPs act primarily by inhibiting acetylcholinesterase (AChE), thereby allowing acetylcholine to accumulate at cholinergic synapses, disturbing transmission at parasympathetic nerve endings, sympathetic ganglia, neuromuscular endplates and certain CNS regions. Atropine is the mainstay of treatment of effects mediated by muscarine sensitive receptors; however, atropine is ineffective at the nicotine sensitive synapses. At both receptor types, reactivation of inhibited AChE may improve the clinical picture.

The value of oximes, however, is still a matter of controversy. Enthusiastic reports of outstanding antidotal effectiveness, substantiated by laboratory findings of reactivated AChE and improved neuromuscular transmission, contrast with many reports of disappointing results. In vitro studies with human erythrocyte AChE, which is derived from the same single gene as synaptic AChE, revealed marked differences in the potency and efficacy of pralidoxime, obidoxime, HI 6 and HLö 7, the latter two oximes being considered particularly effective in nerve agent poisoning. Moreover, remarkable species differences in the susceptibility to oximes were revealed, requiring caution when animal data are extrapolated to humans. These studies impressively demonstrated that any generalisation regarding an effective oxime concentration is inappropriate. Hence, the 4 mg/L concept should be dismissed.

To antagonise the toxic effects of the most frequently used OPs, pralidoxime plasma concentrations of around 80 μmol/L (13.8 mg/L pralidoxime chloride) should be attained while obidoxime plasma concentrations of 10 μmol/L (3.6 mg/L obidoxime chloride) may be sufficient. These concentrations should be maintained as long as circulating poison is expected to be present, which may require oxime therapy for up to 10 days. Various dosage regimens exist to reach this goal. The most appropriate consists of a bolus short infusion followed by a maintenance dosage. For pralidoxime chloride, a 1g bolus over 30 minutes followed by an infusion of 0.5 g/h appears appropriate to maintain the target concentration of about 13 mg/L (70kg person). For obidoxime chloride, the appropriate dosage is a 0.25g bolus followed by an infusion of 0.75 g/24h. These concentrations are well tolerated and keep a good portion of AChE in the active state, thereby retarding the AChE aging rate.

AChE aging is particularly rapid with dimethyl phosphoryl compounds and may thwart the effective reactivation by oximes, particularly in suicidal poisoning with excessive doses. In contrast, patients with diethyl OP poisoning may particularly benefit from oxime therapy, even if no improvement is seen during the first days when the poison load is high. The low propensity to aging with diethyl OP poisoning may allow reactivation after several days, when the poison concentration drops.

Rigorous testing of the benefits of oximes is only possible in randomised controlled trials with clear stratification according to the class of pesticides involved, time elapsed between exposure and treatment and severity of cholinergic symptoms on admission.

References

  1. 1.
    Roberts DM, Karunarathna A, Buckley N, et al. Influence of pesticide regulation on acute poisoning deaths in Sri Lanka. Bull World Health Organ 2003; 81: 789–98PubMedGoogle Scholar
  2. 2.
    Jeyaratnam J. Acute pesticide poisoning: a major global health problem. World Health Stat Q 1990; 43(3): 139–44PubMedGoogle Scholar
  3. 3.
    Eddieston M. Patterns and problems of deliberate self-poisoning in the developing world. Q J Med 2000; 93: 715–31CrossRefGoogle Scholar
  4. 4.
    Gunnell D, Eddieston M. Suicide by intentional ingestion of pesticides: a continuing tragedy in developing countries. Int J Epidemiol 2003; 32: 902–9PubMedCrossRefGoogle Scholar
  5. 5.
    Phillips MR, Li X, Zhang Y. Suicide rates in China, 1995–1999. Lancet 2002; 359: 835–40PubMedCrossRefGoogle Scholar
  6. 6.
    Eddleston M, Szinicz L, Eyer P, et al. Oximes in acute organophosphate poisoning: a systematic review of clinical trials. Q J Med 2002; 95: 1–9CrossRefGoogle Scholar
  7. 7.
    Eddleston M, Karalliedde L, Buckley N, et al. Pesticide poisoning in the developing world: a minimum pesticide list. Lancet 2002; 360: 1163–7PubMedCrossRefGoogle Scholar
  8. 8.
    Black RM, Harrison JM, editors. The chemistry of organophosphorus chemical warfare agents. Chichester: John Wiley, 1996Google Scholar
  9. 9.
    Schrader G. Organische Phosphor-Verbindungen als neuartige Insektizide. Angew Chemie 1950; 62: 471–3CrossRefGoogle Scholar
  10. 10.
    Jennings LL, Malecki M, Komives EA, et al. Direct analysis of the kinetic profiles of organophosphate-acetylcholinesterase adducts by MALDI-TOF mass spectrometry. Biochemistry 2003; 42: 11083–91PubMedCrossRefGoogle Scholar
  11. 11.
    Doom JA, Thompson CM, Christner RB, et al. Stereoselective inactivation of Torpedo californica acetylcholinesterase by isomalathion: inhibitory reactions with (1R)- and (1-S)-isomers proceed by different mechanisms. Chem Res Toxicol 2003; 16: 958–65CrossRefGoogle Scholar
  12. 12.
    Worek F, Kirchner T, Bäcker M, et al. Reactivation by various oximes of human erythrocyte acetylcholinesterase inhibited by different organophosphorus compounds. Arch Toxicol 1996; 70: 497–503PubMedCrossRefGoogle Scholar
  13. 13.
    Worek F, Diepold C, Eyer P. Dimethylphosphoryl-inhibited human cholinesterases: inhibition, reactivation, and aging kinetics. Arch Toxicol 1999; 73: 7–14PubMedCrossRefGoogle Scholar
  14. 14.
    Worthing CA, editor. The pesticide manual: a world compendium. 7th ed. Lavenham: The British Crop Protection Council, 1983Google Scholar
  15. 15.
    Taylor P, Radic Z. The cholinesterases: from genes to proteins. Annu Rev Pharmacol Toxicol 1994; 34: 281–320PubMedCrossRefGoogle Scholar
  16. 16.
    Mortensen SR, Brimijoin S, Hooper MJ, et al. Comparison of the in vitro sensitivity of rat acetylcholinesterase to chlorpyrifos-oxon: what do tissue IC50 values represent? Toxicol Appl Pharmacol 1998; 148: 46–9PubMedCrossRefGoogle Scholar
  17. 17.
    Taylor P. Anticholinesterase agents. In: Hardman JG, Limbird LE, editors. Goodman and Gilman’s the pharmacological basis of therapeutics. 9th ed. New York: McGraw-Hill, 1996: 161–76Google Scholar
  18. 18.
    Schaffer NK, Engle RR, Simet L, et al. Phosphopeptides from chymotrypsin and trypsin after inactivation with 32P-labelled DFP and sarin. J Biochem 1958; 230: 185–92Google Scholar
  19. 19.
    Johnson MK. Organophosphorus esters causing delayed neurotoxic effects: mechanism of action and structure/activity studies. Arch Toxicol 1975; 34: 259–88PubMedCrossRefGoogle Scholar
  20. 20.
    Williams DJ, Johnson MK. Gel-electrophoretic identification of hen brain neurotoxic esterase, labelled with tritiated di-isopropyl phosphofluoridate. Biochem J 1981; 199: 323–33PubMedGoogle Scholar
  21. 21.
    Pope CN. Organophosphorus pesticides: do they all have the same mechanism of toxicity? J Toxicol Environ Health B Crit Rev 1999; 2(2): 161–81PubMedCrossRefGoogle Scholar
  22. 22.
    Lotti M. Clinical toxicology of anticholinesterase agents in humans. In: Krieger RI, editor. Handbook of pesticide toxicology. 2nd ed. San Diego (CA): Academic Press, 2001: 1043–85CrossRefGoogle Scholar
  23. 23.
    Burgen ASV. The mechanism of action of anticholinesterase drugs. Br J Pharmacol 1949; 4: 219–28Google Scholar
  24. 24.
    Burgen ASV, Hobbiger F. The inhibition of cholinesterases by alkylphosphates and alkylphenolphosphates. Br J Pharmacol 1951; 6: 593–605Google Scholar
  25. 25.
    Jansz HS, Brons D, Warringa MGPJ. Chemical nature of the DFP-binding site of pseudocholinesterase. Biochim Biophys Acta 1959; 34: 573–5PubMedCrossRefGoogle Scholar
  26. 26.
    Schaffer NK, May SC, Summerson WH. Serine phosphoric acid from di-isopropylphosphoryl chymotrypsin. J Biol Chem 1953; 202: 67–76PubMedGoogle Scholar
  27. 27.
    MacPhee-Quingley K, Taylor P, Taylor S. Primary structures of the catalytic subunits from two molecular forms of acetylcholinesterase: a comparison of NH2-terminal and active center sequences. J Biol Chem 1985; 260: 12185–9Google Scholar
  28. 28.
    Sussman JL, Harel M, Frolow F, et al. Atomic structure of acetylcholinesterase from Torpedo californica: a prototypic acetylcholine-binding protein. Science 1991; 253: 872–9PubMedCrossRefGoogle Scholar
  29. 29.
    Kovarik Z, Radic Z, Berman HA, et al. Acetylcholinesterase active centre and gorge conformations analysed by combinatorial mutations and enantiomeric phosphonates. Biochem J 2003; 373: 33–40PubMedCrossRefGoogle Scholar
  30. 30.
    Johnson MK, Jacobsen D, Meredith TJ, et al. Evaluation of antidotes for poisoning by organophosphorus pesticides. Emerg Med 2000; 12: 22–37CrossRefGoogle Scholar
  31. 31.
    Aldridge WN, Reiner E. Enzyme inhibitors as substrates: interactions of esterases with esters of organophosphorus and carbamic acids. Amsterdam: North-Holland Publishing Co., 1972Google Scholar
  32. 32.
    Eyer F, Eyer P. Enzyme-based assay for quantification of paraoxon in blood of parathion poisoned patients. Hum Exp Toxicol 1998; 17: 645–51PubMedCrossRefGoogle Scholar
  33. 33.
    Cohen SD, Williams RA, Killinger JM, et al. Comparative sensitivity of bovine and rodent acetylcholinesterase to in vitro inhibition by organophosphate insecticides. Toxicol Appl Pharmacol 1985; 81: 452–9PubMedCrossRefGoogle Scholar
  34. 34.
    Johnson JA, Wallac KB. Species-related differences in the inhibition of brain acetylcholinesterase by paraoxon and malaoxon. Toxicol Appl Pharmacol 1987; 88: 234–41PubMedCrossRefGoogle Scholar
  35. 35.
    Wilson IB, Meislich EK. Reactivation of acetylcholinesterase inhibited by alkylphosphates. J Am Chem Soc 1953; 75: 4628–9CrossRefGoogle Scholar
  36. 36.
    Radic Z, Taylor P. The influence of peripheral site ligands on the reaction of symmetric and chiral organophosphates with wildtype and mutant acetylcholinesterases. Chem Biol Interact 1999; 119: 111–7PubMedCrossRefGoogle Scholar
  37. 37.
    Amitai G, Moorad D, Adani R, et al. Inhibition of acetylcholinesterase and butyrylcholinesterase by chlorpyrifos-oxon. Biochem Pharmacol 1998; 56: 293–9PubMedCrossRefGoogle Scholar
  38. 38.
    Worek F, Bäcker M, Thiermann H, et al. Reappraisal of indications and limitations of oxime therapy in organophosphate poisoning. Hum Exp Toxicol 1997; 16: 466–72PubMedCrossRefGoogle Scholar
  39. 39.
    Skrinjaric-Spoljar M, Simeon V, Reiner E. Spontaneous reactivation and aging of dimethylphosphorylated acetylcholinesterase and cholinesterase. Biochim Biophys Acta 1973; 315: 363–9CrossRefGoogle Scholar
  40. 40.
    Mason HJ, Waine E, Stevenson A, et al. Aging and spontaneous reactivation of human plasma cholinesterase activity after inhibition by organophosphorus pesticides. Hum Exp Toxicol 1993; 12: 497–503PubMedCrossRefGoogle Scholar
  41. 41.
    Hobbiger F. Inhibition of cholinesterases by irreversible inhibitors in vitro and in vivo. Br J Pharmacol 1951; 6: 21–30Google Scholar
  42. 42.
    Wilson IB. Acetylcholinesterase XI: reversibility of tetraethylpyrophosphate inhibition. J Biol Chem 1951; 190: 111–7PubMedGoogle Scholar
  43. 43.
    Wilson IB, Ginsburg S. A powerful reactivator of alkylphosphate-inhibited acetylcholinesterase. Biochim Biophys Acta 1955; 18: 168–70PubMedCrossRefGoogle Scholar
  44. 44.
    Childs AF, Davies DR, Green AL, et al. The reactivation by oximes and hydroxamic acids of cholinesterase inhibited by organo-phosphorus compounds. Br J Pharmacol 1955; 10: 462–5Google Scholar
  45. 45.
    Hobbiger F. Effect of nicotinhydroxamic acid methiodide on human plasma cholinesterase inhibited by organophosphates containing a dialkylphosphato group. Br J Pharmacol 1955; 10: 356–62Google Scholar
  46. 46.
    Berends F, Posthumus CH, Sluys IVD, et al. The chemical basis of the ‘ageing process’ of DFP-inhibited pseudocholinesterase. Biochim Biophys Acta 1959; 34: 576–9CrossRefGoogle Scholar
  47. 47.
    Saxena A, Doctor BP, Maxwell DM, et al. The role of glutamate-199 in the aging of cholinesterase. Biochem Biophys Res Commun 1993; 197: 343–9PubMedCrossRefGoogle Scholar
  48. 48.
    Shafferman A, Ordentlich A, Barak D, et al. Aging of phosphylated human acetylcholinesterase: catalytic processes mediated by aromatic and polar residues of the active centre. Biochem J 1996; 318: 833–40PubMedGoogle Scholar
  49. 49.
    Masson P, Fortier P-L, Albaret C, et al. Structural and hydration changes in the active site gorge of phosphorylated butyrylcholinesterase accompanying the ageing process. Chem-Biol Interact 1999; 119-120: 17–27PubMedCrossRefGoogle Scholar
  50. 50.
    Barak D, Ordentlich A, Kaplan D, et al. Evidence for P-N bond scission in phosphoroamidate nerve agent adducts of human acetylcholinesterase. Biochemistry 2000; 39: 1156–61PubMedCrossRefGoogle Scholar
  51. 51.
    Besser R, Weilemann LS, Schollmeyer U, et al. Synaptic transmisson during pesticide poisoning: the neuromuscular block. In: Szinicz L, Eyer P, Klimmek R, editors. Role of oximes in the treatment of anticholinesterase agent poisoning. Heidelberg: Spektrum, Akademischer Verlag, 1996: 19–31Google Scholar
  52. 52.
    Ludomirsky A, Klein HO, Sarelli P, et al. Q-T prolongation and polymorphous (‘torsade de pointes’) ventricular arrhythmias associated with organophosphorus insecticide poisoning. Am J Cardiol 1982; 49: 1654–8PubMedCrossRefGoogle Scholar
  53. 53.
    Savolainen K. Understanding the toxic actions of organophosphates. In: Krieger RI, editor. Handbook of pesticide toxicology. 2nd ed. San Diego: Academic Press, 2001: 1013–41CrossRefGoogle Scholar
  54. 54.
    Besser R, Gutman L, Weilemann LS. Inactivation of end-plate acetylcholinesterase during the course of organophosphate intoxications. Arch Toxicol 1989; 63: 412–5PubMedCrossRefGoogle Scholar
  55. 55.
    Besser R, Gutmann L, Dillmann U, et al. End-plate dysfunction in acute organophosphate intoxication. Neurology 1989; 39: 561–7PubMedCrossRefGoogle Scholar
  56. 56.
    Kauert G, Schoppek B, von Clarmann M, et al. Plasma-Katecholamin-Verlauf bei Alkylphosphat-Intoxikationen und deren Therapie. Klin Wochenschr 1989; 67: 456–62PubMedCrossRefGoogle Scholar
  57. 57.
    Kauert G, Schoppek B, von Clarmann M, et al. Plasma- und Urin-Katecholamine bei einer 7 Tage überlebten Parathion-Intoxikation. Klin Wochenschr 1990; 68: 96–100PubMedCrossRefGoogle Scholar
  58. 58.
    Suzuki T, Morita H, Ono K, et al. Sarin poisoning in Tokyo subway. Lancet 1995; 345: 980PubMedCrossRefGoogle Scholar
  59. 59.
    Sidell F. Nerve agents. In: Sidell F, Takafuji ET, Franz DR, editors. Medical aspects of chemical and biological warfare. Washington, DC: Walter Reed Army Medical Center, 1997: 130–79Google Scholar
  60. 60.
    Namba T, Nolte CT, Jackrel J, et al. Poisoning due to organophosphate insecticides: acute and chronic manifestations. Am J Med 1971; 50: 475–92PubMedCrossRefGoogle Scholar
  61. 61.
    Wadia RS, Sadagopan C, Amin RB, et al. Neurological manifestations of organophosphorous insecticide poisoning. J Neurol Neurosurg Psychiatry 1974; 37: 841–7PubMedCrossRefGoogle Scholar
  62. 62.
    Senanayake N, Karalliedde L. Neurotoxic effects of organophosphorus insecticides: an intermediate syndrome. N Engl J Med 1987; 316: 761–3PubMedCrossRefGoogle Scholar
  63. 63.
    Eddleston M, Singh S, Buckley N. Acute organophosphate poisoning. Clin Evid 2002; 8: 1436–46PubMedGoogle Scholar
  64. 64.
    Zwiener RJ, Ginsburg CM. Organophosphate and carbamate poisoning in infants and children. Pediatrics 1988; 81: 121–6PubMedGoogle Scholar
  65. 65.
    Eyer F, Meischner V, Kiderlen D, et al. Human parathion poisoning: a toxicokinetic analysis. Toxicol Rev 2003; 22(3): 143–63PubMedCrossRefGoogle Scholar
  66. 66.
    Guven H, Tuncok Y, Gidener S, et al. In vitro adsorption of dichlorvos and parathion by activated charcoal. J Toxicol Clin Toxicol 1994; 32: 157–63PubMedCrossRefGoogle Scholar
  67. 67.
    Tuncok Y, Gelai A, Apaydin S, et al. Prevention of oral dichlorvos toxicity by different activated charcoal products in mice. Ann Emerg Med 1995; 25: 353–5PubMedCrossRefGoogle Scholar
  68. 68.
    Tomimaru A, Arimori K, Inotsume N, et al. Effect of activated charcoal and atropine on absorption and/or exsorption of organophosphorus compounds in rats. J Pharm Pharmacol 1996; 48: 351–6PubMedCrossRefGoogle Scholar
  69. 69.
    Simpson Jr WM, Schuman SH. Recognition and management of acute pesticide poisoning. Am Fam Physician 2002; 65: 1599–604PubMedGoogle Scholar
  70. 70.
    Marrs TC. Organophosphate poisoning. Pharmacol Ther 1993; 58: 51–66PubMedCrossRefGoogle Scholar
  71. 71.
    Vale JA, Scott GW. Organophosphorus poisoning. Guys Hosp Rep 1974; 123: 13–25PubMedGoogle Scholar
  72. 72.
    Minton NA, Murray VSG. A review of organophosphate poisoning. Med Toxicol 1988; 3: 350–75CrossRefGoogle Scholar
  73. 73.
    Eddleston M, Singh S, Buckley N. Acute organophosphorus poisoning. Clin Evid 2003; 9: 1542–53PubMedGoogle Scholar
  74. 74.
    Grob D. The manifestations and treatment of poisoning due to nerve gas and other organic phosphate anticholinesterase compounds. Arch Intern Med 1956; 98: 221–39CrossRefGoogle Scholar
  75. 75.
    Aaron CK, Howland MA. Insecticides: organophosphates and carbamates. In: Goldfrank TR, Flomenbaum NE, Lewin NA, et al., editors. Toxicologic emergencies. Norwalk (CT): Appleton & Lange, 1994: 1111Google Scholar
  76. 76.
    Thiermann H, Worek F, Szinicz L, et al. On the atropine demand in organophosphate poisoned patients. J Toxicol Clin Toxicol 2003; 41: 457Google Scholar
  77. 77.
    Golsousidis H, Kokkas V. Use of 19590mg atropine during 24 days of treatment after a case of unusually severe parathion poisoning. Hum Toxicol 1985; 4: 339–40PubMedCrossRefGoogle Scholar
  78. 78.
    LeBlanc FN, Benson BE, Gilg AD. A severe organophosphate poisoning requiring the use of an atropine drip. J Toxicol Clin Toxicol 1986; 24: 69–76PubMedCrossRefGoogle Scholar
  79. 79.
    Helm U. Nervenkampfstoffvergiftung (Alkylphosphatvergiftung). In: Rebentisch E, editor. Wehrmedizin. München: Urban & Schwarzenberg, 1980Google Scholar
  80. 80.
    Heath AJW, Meredith T. Atropine in the management of anticholinesterase poisoning. In: Ballantyne B, Marrs TC, editors. Clinical and experimental toxicology of organophosphates and carbamates. Oxford: Butterworth-Heinemann Ltd, 1992: 543–54Google Scholar
  81. 81.
    De Kort WLAM, Kiestra SH, Sangster B. The use of atropine and oximes in organosphosphate intoxications: a modified approach. J Toxicol Clin Toxicol 1988; 26: 199–208PubMedCrossRefGoogle Scholar
  82. 82.
    Namba T, Hiraki K. PAM (pyridine-2-aldoxime methiodide) therapy for alkylphosphate poisoning. JAMA 1958; 166: 1834–9CrossRefGoogle Scholar
  83. 83.
    Lüttringhaus A, Hagedorn I. Quartäre Hydroxyiminomethyl-pyridiniumsalze: das dichlorid des bis-[4-hydroxyiminomethyl-pyridinium-(1)-methyl]-äthers (‘LüH6’), ein neuer Reaktivator der durch organische Phosphorsäureester gehemmten Acetylcholin-Esterase. Arzneimittel Forschung 1964; 14: 1–5Google Scholar
  84. 84.
    Erdmann WD, von Clarmann M. Ein neuer Esterase-Reaktivator für die Behandlung von Vergiftungen mit Alkylphosphaten. Dtsch Med Wochenschr 1963; 88: 2201–6PubMedCrossRefGoogle Scholar
  85. 85.
    Oettel H. Erfahrungen einer Giftinformationsstelle. Dtsch Ärztebl 1967; 64: 2787–91Google Scholar
  86. 86.
    De Silva HJ, Wijewickrema R, Senanayake N. Does pralidoxime affect outcome of management in acute organophosphate poisoning? Lancet 1992; 339: 1136–8PubMedCrossRefGoogle Scholar
  87. 87.
    Johnson MK, Vale JA, Marrs TC, et al. Pralidoxime for organophosphorus poisoning. Lancet 1992; 340: 64PubMedCrossRefGoogle Scholar
  88. 88.
    Ashani Y, Radic Z, Tsigelny I, et al. Amino acid residues controlling reactivation of organophosphonyl conjugates of acetylcholinesterase by mono- and bis-quaternary oximes. J Biol Chem 1995; 270: 6370–80PubMedCrossRefGoogle Scholar
  89. 89.
    Taylor P, Wong L, Radic Z, et al. Analysis of cholinesterase inactivation and reactivation by systematic structural modification and enantiomeric selectivity. Chem Biol Interact 1999; 119-120: 3–15PubMedCrossRefGoogle Scholar
  90. 90.
    Parfitt K, editor. Martindale. The complete drug reference. 32nd ed. London: The Pharmaceutical Press, 1999Google Scholar
  91. 91.
    Eyer P, Hagedorn I, Klimmek R, et al. HLö 7 dimethanesulfonate, a potent bispyridinium-dioxime against anticholinesterases. Arch Toxicol 1992; 66: 603–21PubMedCrossRefGoogle Scholar
  92. 92.
    Clement JG, Hansen AS, Boulet CA. Efficacy of HLö-7 and pyrimidoxime as antidotes of nerve agent poisoning in mice. Arch Toxicol 1992; 66: 216–9PubMedCrossRefGoogle Scholar
  93. 93.
    Worek F, Reiter G, Eyer P, et al. Reactivation kinetics of acetylcholinesterase from different species inhibited by highly toxic organophosphates. Arch Toxicol 2002; 76: 523–9PubMedCrossRefGoogle Scholar
  94. 94.
    Kusic R, Boskovic B, Vojvodic V, et al. HI-6 in man: blood levels, urinary excretion, and tolerance after intramuscular administration of the oxime to healthy volunteers. Fundam Appl Toxicol 1985; 5: S89–97PubMedCrossRefGoogle Scholar
  95. 95.
    Rousseaux CG, Dua AK. Pharmacology of HI-6, an H-series oxime. Can J Physiol Pharmacol 1989; 67: 1183–9PubMedCrossRefGoogle Scholar
  96. 96.
    Clement JG, Madill HD, Bailey D, et al. Clinical study of a new therapy for nerve agent poisoning: ascending dose tolerance study of HI 6 and atropine. Suffield: Defense Research Establishment, 1994. Report no. 597Google Scholar
  97. 97.
    Schlager JW, Dolzine TW, Stewart JR, et al. Operational evaluation of three commercial configurations of atropine/HI-6 wet/dry autoinjectors. Pharm Res 1991; 8: 1191–4PubMedCrossRefGoogle Scholar
  98. 98.
    Thiermann H, Spöhrer U, Klimmek R, et al. Operational evaluation of wet/dry autoinjectors containing atropine in solution and powdered HI 6 or HLö 7. Int J Pharm 1994; 109: 35–43CrossRefGoogle Scholar
  99. 99.
    Göransson-Nyberg A, Cassel G, Jeneskog T, et al. Treatment of organophosphate poisoning in pigs: antidote administration by a new binary autoinjector. Arch Toxicol 1995; 70: 20–7PubMedCrossRefGoogle Scholar
  100. 100.
    Clement JG. Toxicity of the combined nerve agents GB/GF in mice: efficacy of atropine and various oximes as antidotes. Arch Toxicol 1994; 68: 64–6PubMedGoogle Scholar
  101. 101.
    Green AL, Saville B. The reaction of oximes with isopropyl methylphosphonofluoridate (sarin). J Chem Soc 1956; 3: 3887–92CrossRefGoogle Scholar
  102. 102.
    Hackley Jr BE, Steinberg GM, Lamb JC. Formation of potent inhibitors of AChE by reaction of pyridinaldoximes with isopropyl methylphosphonofluoridate (GB). Arch Biochem Biophys 1959; 80: 211–4CrossRefGoogle Scholar
  103. 103.
    Portmann R, Niederhauser A, Hofmann W, et al. 32. Synthesis of 4-(([(isopropyloxy)methylphosphoryloxy]imino)methyl)-1-methylpyridinium iodide and its characterisation. Helv Chim Acta 1991; 74: 331–5CrossRefGoogle Scholar
  104. 104.
    Becker G, Kawan A, Szinicz L. Direct reaction of oximes with sarin, soman, or tabun in vitro. Arch Toxicol 1997; 71: 714–8PubMedCrossRefGoogle Scholar
  105. 105.
    Leader H, Vincze A, Manisterski B, et al. Characterization of O,O-diethylphosphoryl oximes as inhibitors of cholinesterases and substrates of phosphotriesterases. Biochem Pharmacol 1999; 58: 503–15PubMedCrossRefGoogle Scholar
  106. 106.
    Luo C, Saxena A, Smith M, et al. Phosphoryl oxime inhibition of acetylcholinesterase during oxime reactivation is prevented by edrophonium. Biochemistry 1999; 38: 9937–47PubMedCrossRefGoogle Scholar
  107. 107.
    Lamb JC, Steinberg GM, Hackley Jr BE. Isopropyl methylphosphonylated bis-quaternary oximes; powerful inhibitors of cholinesterase. Biochim Biophys Acta 1964; 89: 174–6PubMedGoogle Scholar
  108. 108.
    Nenner M. Phosphonylierte aldoxime: hemmwirkung auf acetylcholinesterase und hydrolytischer abbau. Biochem Pharmacol 1974; 23: 1255–62PubMedCrossRefGoogle Scholar
  109. 109.
    De Jong LPA, Ceulen DI. Anticholinesterase activity and rate of decomposition of some phosphylated oximes. Biochem Pharmacol 1978; 27: 857–63PubMedCrossRefGoogle Scholar
  110. 110.
    Harvey B, Scott RP, Sellers DJ, et al. In vitro studies on the reactivation by oximes of phosphylated acetylcholinesterase, I: on the reactions of P2S with various organophosphates and the properties of the resultant phosphylated oximes. Biochem Pharmacol 1986; 35: 737–44PubMedCrossRefGoogle Scholar
  111. 111.
    Lockridge O, Masson P. Pesticides and susceptible populations: people with butyrylcholinesterase genetic variants may be at risk. Neurotoxicology 2000; 21: 113–26PubMedGoogle Scholar
  112. 112.
    Kiderlen D, Worek F, Klimmek R, et al. The phosphoryl oxime-destroying activity of human plasma. Arch Toxicol 2000; 74: 27–32PubMedCrossRefGoogle Scholar
  113. 113.
    Worek F, Eyer P, Kiderlen D, et al. Effect of human plasma on the reactivation of sarin-inhibited human erythrocyte acetylcholinesterase. Arch Toxicol 2000; 74: 21–6PubMedCrossRefGoogle Scholar
  114. 114.
    Kiderlen D, Meischner V, Worek F, et al. Phosphoryl oxime-hydrolase in human serum influences oxime effectiveness in organophosphate poisoning. Drug Metab Rev 2001; 33Suppl. 1: 110Google Scholar
  115. 115.
    Hagedorn I, Gündel WH, Schoene K. Reaktivierung phosphorylierter acetylcholinesterase mit oximen: beitrag zum Studium des reaktionsablaufes. Arzneimittel Forschung 1969; 19: 603–6PubMedGoogle Scholar
  116. 116.
    Eyer P. Optimal oxime dosage regimen, a pharmacokinetic approach. In: Szinicz L, Eyer P, Klimmek R, editors. Role of oximes in the treatment of anticholinesterase agent poisoning. Heidelberg: Spektrum, Akademischer Verlag, 1996: 33–51Google Scholar
  117. 117.
    Ellin RI, Groff WA, Sidell FR. Passage of pyridinium oximes into human red cells. Biochem Pharmacol 1974; 23: 2663–70PubMedCrossRefGoogle Scholar
  118. 118.
    Spöhrer U. HPLC-analytische Untersuchungen zur Pharmakokinitk von Pyridiniumaldoximen [dissertation]. Munich: Ludwig-Maximilians-University, 1994Google Scholar
  119. 119.
    Sidell FR, Groff WA, Kaminskis A. Toxogonin and pralidoxime: kinetic comparison after intravenous administration to man. J Pharm Sci 1972; 61: 1765–9PubMedCrossRefGoogle Scholar
  120. 120.
    Josselson J, Sidell FR. Effect of intravenous thiamine on pralidoxime kinetics. Clin Pharmacol Ther 1978; 24: 95–100PubMedGoogle Scholar
  121. 121.
    Jovanovic D. Pharmacokinetics of pralidoxime chloride: a comparative study in healthy volunteers and in organophosphorus poisoning. Arch Toxicol 1989; 63: 416–8PubMedCrossRefGoogle Scholar
  122. 122.
    Willems JL, Langenberg JP, Verstraete AG, et al. Plasma concentrations of pralidoxime methylsulphate in organophosphorus poisoned patients. Arch Toxicol 1992; 66: 260–6PubMedCrossRefGoogle Scholar
  123. 123.
    Clement JG, Bailey DG, Madill HD, et al. The acetylcholinesterase oxime reactivator HI-6 in man: pharmacokinetics and tolerability in combination with atropine. Biopharm Drug Dispos 1995; 16: 415–25PubMedCrossRefGoogle Scholar
  124. 124.
    Bentur Y, Nutenko I, Tsipiniuk A, et al. Pharmacokinetics of obidoxime in organophosphate poisoning associated with renal failure. Clin Toxicol 1993; 31: 315–22CrossRefGoogle Scholar
  125. 125.
    Waser PG, Sammett R, Schönenberger E, et al. Pharmacokinetics of [14C]-sarin and its changes by obidoxime and pralidoxime. In: Hanin I, editor. Dynamics of cholinergic function. New York: Plenum Press, 1986: 743–55CrossRefGoogle Scholar
  126. 126.
    Waser PG, Streichenberg C. Metabolism, kinetics and interaction of 14C-sarin and 14C-obidoxime. Toxicol Environ Chem 1988; 18: 1–10CrossRefGoogle Scholar
  127. 127.
    Ligtenstein DA, Moes GWH, Kossen SP. In vivo distribution of organophosphate antidotes: autoradiography of [14C]HI-6 in the rat. Toxicol Appl Pharmacol 1988; 92: 324–9PubMedCrossRefGoogle Scholar
  128. 128.
    Garrigue H, Maurizis JC, Nicolas C, et al. Disposition and metabolism of two acetylcholinesterase reactivators, pyrimidoxime and HI6, in rats submitted to organophosphate poisoning. Xenobiotica 1990; 20: 699–709PubMedCrossRefGoogle Scholar
  129. 129.
    Garrigue H, Maurizis JC, Madelmont JC, et al. Disposition and metabolism of acetylcholinesterase reactivators 2PAM-I, TMB4 and R665 in rats submitted to organophosphate poisoning. Xenobiotica 1991; 21: 583–95PubMedCrossRefGoogle Scholar
  130. 130.
    Boyd ES, Neuman WF. The surface chemistry of bone: V. the ion-binding properties of cartilage. J Biol Chem 1951; 193: 243–51PubMedGoogle Scholar
  131. 131.
    Dunstone JR. Some cation-binding properties of cartilage. Biochem J 1959; 72: 465–73PubMedGoogle Scholar
  132. 132.
    Maurizis JC, Ollier M, Nicolas C, et al. In vitro binding of oxime acetylcholinesterase reactivators to proteoglycans synthesized by cultured chondrocytes and fibroblasts. Biochem Pharmacol 1992; 44: 1927–33PubMedCrossRefGoogle Scholar
  133. 133.
    Sakurada K, Matsubara K, Shimizu K, et al. Pralidoxime iodide (2-PAM) penetrates across the blood-brain barrier. Neurochem Res 2003; 28: 1401–7PubMedCrossRefGoogle Scholar
  134. 134.
    Jager BV, Stagg GN, Green N, et al. Studies on distribution and disappearance of pyridine-2-aldoxime methiodide (PAM) and of diacetylmonoxime (DAM) in man and in experimental animals. Bull Johns Hopkins Hosp 1958; 102: 225–34PubMedGoogle Scholar
  135. 135.
    Lotti M, Becker CE. Treatment of acute organophosphate poisoning: evidence of a direct effect on central nervous system by 2-PAM (pyridine-2-aldoxime methyl chloride). Clin Toxicol 1982; 19: 121–7CrossRefGoogle Scholar
  136. 136.
    Ligtenstein DA, Kossen SP. Kinetic profile in blood and brain of the cholinesterase reactivating oxime HI-6 after intravenous administration to the rat. Toxicol Appl Pharmacol 1983; 71: 177–83PubMedCrossRefGoogle Scholar
  137. 137.
    Klimmek R, Eyer P. Pharmacokinetics and pharmacodynamics of the oxime HI 6 in dogs. Arch Toxicol 1986; 59: 272–8PubMedCrossRefGoogle Scholar
  138. 138.
    Tochino Y, Schanker LS. Active transport of quaternary ammonium compounds by the choroid plexus in vitro. Am J Physiol 1965; 208: 666–73PubMedGoogle Scholar
  139. 139.
    Grange-Messent V, Bouchaud C, Jamme M, et al. Seizure-related opening of the blood-brain barrier produced by the anticholinesterase compound, soman: new ultrastructural observations. Cell Mol Biol 1999; 45: 1–14PubMedGoogle Scholar
  140. 140.
    Enander I, Sundwall A, Sörbo B. Metabolic studies on N-methylpyridinium-2-aldoxime, III: experiments with the 14C-labelled compound. Biochem Pharmacol 1962; 11: 377–82PubMedCrossRefGoogle Scholar
  141. 141.
    Enander I, Sundwall A, Sörbo B. Metabolic studies on N-methylpyridinium-2-aldoxime, I: the conversion to thiocyanate. Biochem Pharmacol 1961; 7: 226–31PubMedCrossRefGoogle Scholar
  142. 142.
    Enander I, Sundwall A, Sörbo B. Metabolic studies on N-methylpyridinium-2-aldoxime, II: the conversion to N-methylpyridinium-2-nitrile. Biochem Pharmacol 1961; 7: 232–6PubMedCrossRefGoogle Scholar
  143. 143.
    Ligtenstein DA, Wils ERJ, Kossen SP, et al. Identification of two metabolites of the cholinesterase reactivator HI-6 isolated from rat urine. J Pharm Pharmacol 1987; 39: 17–23PubMedCrossRefGoogle Scholar
  144. 144.
    Eyer P, Kawan A, Ladstetter B. Formation of cyanide after i.v. administration of the oxime HI 6 to dogs. Arch Toxicol 1987; 61: 63–9PubMedCrossRefGoogle Scholar
  145. 145.
    Ladstetter B. Stabilität und metabolisches Schicksal neuer Antidote gegen Organophosphate [dissertation]. Munich: Ludwig-Maximilians-University, 1990Google Scholar
  146. 146.
    Eyer P, Hell W, Kawan A, et al. Studies on the decomposition of the oxime HI 6 in aqueous solution. Arch Toxicol 1986; 59: 266–71PubMedCrossRefGoogle Scholar
  147. 147.
    Creasey HN, Green AC. 2-Hydroxyiminomethyl-N-methyl-pyridiniummethansulfonate (P2S), an antidote to organophosphorus poisoning: its preparation, estimation, and stability. J Pharm Pharmacol 1959; 11: 485–90PubMedCrossRefGoogle Scholar
  148. 148.
    Sidell FR, Groff WA. Toxogonin: blood levels and side effects after intramuscular administration in man. J Pharm Sci 1970; 59: 793–7PubMedCrossRefGoogle Scholar
  149. 149.
    Erdmann WD, Bosse I, Franke P. Zur Resorption und Ausscheidung von Toxogonin nach intramuskulärer Injektion am Menschen. Dtsch Med Wochenschr 1965; 90: 1436–8PubMedCrossRefGoogle Scholar
  150. 150.
    Thiermann H, Worek F, Szinicz L, et al. Obidoxime plasma levels in organophosphate poisoned patients. J Toxicol Clin Toxicol 2002; 40: 318–9Google Scholar
  151. 151.
    Kusic R, Jovanovic D, Randjelovic S, et al. HI-6 in man: efficacy of the oxime in poisoning by organophosphorus insecticides. Hum Exp Toxicol 1991; 10: 113–8PubMedCrossRefGoogle Scholar
  152. 152.
    Schulz V, Gross R, Pasch T, et al. Cyanide toxicity of sodium nitroprusside in therapeutic use with and without sodium thiosulfate. Klin Wochenschr 1982; 60: 1393–400PubMedCrossRefGoogle Scholar
  153. 153.
    Green MD, Jones DE, Hilmas DE. Sarin intoxication elevates plasma pralidoxime. Toxicol Lett 1985; 28: 17–21PubMedCrossRefGoogle Scholar
  154. 154.
    Mast U. Reaktivierung der Erythrozyten-Acetylcholinesterase durch Oxime: ermittlung enzymkinetischer Konstanten und ihre Bedeutung für die Therapie einer Organophosphat-Vergiftung, [dissertation]. Munich: Ludwig-Maximilians-University, 1997Google Scholar
  155. 155.
    Jager BV, Stagg GN. Toxicity of diacetylmonoxime and of pyridine-2-aldoxime methiodide in man 15–30 mg/kg 2-PAM: no effects on EEG in a healthy man. Bull Johns Hopkins Hosp 1958; 102: 203–11PubMedGoogle Scholar
  156. 156.
    Sundwall A. Plasma concentration curves of N-methylpyridinium-2-aldoxime methane sulphonate (P2S) after intravenous, intramuscular and oral administration in man. Biochem Pharmacol 1960; 5: 225–30CrossRefGoogle Scholar
  157. 157.
    Calesnick B, Christensen JA, Richter M. Human toxicity of various oximes: 2-pyridine aldoxime methyl chloride, its methane sulfonate salt, and 1,1′-trimethylenebis-(4-formylpyridinium chloride). Arch Environ Health 1967; 15: 599–608PubMedGoogle Scholar
  158. 158.
    Sidell FR, Groff WA. Intramuscular and intravenous administration of small doses of 2-pyridinium aldoxime methochloride to man. J Pharm Sci 1971; 60: 1224–8PubMedCrossRefGoogle Scholar
  159. 159.
    Xue SZ, Ding XJ, Ding Y. Clinical observation and comparison of the effectiveness of several oxime cholinesterase reactivators. Scand J Work Environ Health 1985; 11: 46–8PubMedGoogle Scholar
  160. 160.
    Medicis JJ, Stork CM, Howland MA, et al. Pharmacokinetics following a loading plus a continuous infusion of pralidoxime compared with the traditional short infusion regimen in human volunteers. Clin Toxicol 1996; 34: 289–95CrossRefGoogle Scholar
  161. 161.
    Scott RJ. Repeated asystole following PAM in organophosphate self-poisoning. Anaesth Intensive Care 1986; 14: 458–60PubMedGoogle Scholar
  162. 162.
    Ellenhorn MJ, Barceloux DG. Medical toxicology: diagnosis and treatment of human poisoning. New York: Elsevier, 1988Google Scholar
  163. 163.
    Simon GA, Tirosh MS, Edery H. Administration of obidoxime tablets to man: plasma levels and side reactions. Arch Toxicol 1976; 36: 83–8PubMedCrossRefGoogle Scholar
  164. 164.
    Boelcke G, Creutzfeldt W, Erdmann WD, et al. Untersuchungen zur Frage der Lebertoxizität von Obidoxim (Toxogonin®) am Menschen. Dtsch Med Wochenschr 1970; 95: 1175–8PubMedCrossRefGoogle Scholar
  165. 165.
    von Gaisberg U, Dieterle K. Organ-Parenchymschäden nach E-605-Vergiftung bzw. hochdosierter Toxogoninbehandlung. Dtsch Arztebl 1967; 64: 1791–6Google Scholar
  166. 166.
    Prinz HJ. Therapie akuter Alkylphosphat-Vergiftungen. Dtsch Arztebl 1967; 36: 1845–9Google Scholar
  167. 167.
    Boelcke G, Gaaz JW. Zur Frage der Lebertoxizität von Nitrostigmin (E605 forte®) und Obidoxim (Toxogonin®) an Hunden. Arch Toxicol 1970; 26: 93–101CrossRefGoogle Scholar
  168. 168.
    Finkelstein Y, Kushnir A, Raikhlin-Eisenkraft B, et al. Antidotal therapy of severe acute organophosphate poisoning: a multihospital study. Neurotoxicol Teratol 1989; 11: 593–6PubMedCrossRefGoogle Scholar
  169. 169.
    Taitelman U. Round table discussion. In: Szinicz L, Eyer P, Klimmek R, editors. Role of oximes in the treatment of anticholinesterase agent poisoning. Heidelberg: Spektrum, Akademischer Verlag, 1996: 78Google Scholar
  170. 170.
    Zech R, Erdmann WD, Engelhard H. Grenzen der Therapie mit Oximen bei Vergiftungen mit Insektiziden Alkylphosphaten. Arzneimittel Forschung 1967; 17: 1196–202PubMedGoogle Scholar
  171. 171.
    Sundwall A. Minimum concentrations of N-methylpyridinium-2-aldoxime methane sulphonate (P2S) which reverse neuromuscular block. Biochem Pharmacol 1961; 8: 413–7PubMedCrossRefGoogle Scholar
  172. 172.
    Erdmann WD. Antidotbehandlung bei Alkylphosphatvergiftungen. Arch Toxicol 1968; 24: 30–40CrossRefGoogle Scholar
  173. 173.
    Vale JA. Rationale for oxime therapy: pralidoxime as an antidote in OP insecticide poisoning [abstract]. Hum Exp Toxicol 1996; 15: 77Google Scholar
  174. 174.
    Thompson DF, Thompson GD, Greenwood RB, et al. Therapeutic dosing of pralidoxime chloride. Drug Intell Clin Pharm 1987; 21: 590–3PubMedGoogle Scholar
  175. 175.
    Farrar HC, Wells TG, Kearns GL. Use of continuous infusion of pralidoxime for treatment of organophosphate poisoning in children. J Pediatr 1990; 116: 658–61PubMedCrossRefGoogle Scholar
  176. 176.
    Willems JL, Belpaire FM. Anticholinesterase poisoning: an overview of pharmacotherapy. In: Ballantyne B, Marrs T, editors. Clinical and experimental toxicology of organophosphates and carbamates. Oxford: Butterworth-Heinemann Ltd, 1992: 536–42Google Scholar
  177. 177.
    Willems JL, De Bisschop HC, Verstraete AG, et al. Cholinesterase reactivation in organophosphorus poisoned patients depends on the plasma concentrations of the oxime pralidoxime methylsulphate and of the organophosphate. Arch Toxicol 1993; 67: 79–84PubMedCrossRefGoogle Scholar
  178. 178.
    Casey PB, Gosden E, Blakely L, et al. Plasma pralidoxime concentrations following bolus injection and continuous infusion [abstract]. Przegl Lek 1995; 52: 203Google Scholar
  179. 179.
    Tush GM, Anstead MI. Pralidoxime continuous infusion in the treatment of organophosphate poisoning. Ann Pharmacother 1997; 31: 441–3PubMedGoogle Scholar
  180. 180.
    Singh S, Chaudhry D, Behera D, et al. Aggressive atropinisation and continuous pralidoxime (2-PAM) infusion in patients with severe organophosphate poisoning: experience of a northwest Indian hospital. Hum Exp Toxicol 2001; 20: 15–8PubMedCrossRefGoogle Scholar
  181. 181.
    Schexnayder S, James LP, Kearns GL, et al. The pharmacokinetics of continuous infusion pralidoxime in children with organophosphate poisoning. Clin Toxicol 1998; 36: 549–55CrossRefGoogle Scholar
  182. 182.
    Green AL, Smith HJ. The reactivation of cholinesterase inhibited with organophosphorus compounds: 1. reactivation by 2-oxoaldoximes. Biochem J 1958; 68: 28–31PubMedGoogle Scholar
  183. 183.
    Furlong CE, Li W-F, Shih DM, et al. Genetic factors in susceptibiliy: serum PON1 variation between individuals and species. Hum Ecol Risk Assess 2002; 8: 31–43CrossRefGoogle Scholar
  184. 184.
    Kiderlen D. On the phosphoryl oxime hydrolase of plasma, an enzyme that markedly increases the efficacy of oximes in organophosphate poisoning [dissertation]. Munich: Ludwig-Maximilians-University, 2003Google Scholar
  185. 185.
    Brophy VH, Jampsa RL, Clendenning JB, et al. Effects of 5′ regulatory-region polymorphism on paraoxonase-gene (PON1) expression. Am J Genet 2001; 68: 1428–36CrossRefGoogle Scholar
  186. 186.
    Dawson RM. Review of oximes available for treatment of nerve agent poisoning. J Appl Toxicol 1994; 14: 317–31PubMedCrossRefGoogle Scholar
  187. 187.
    Kassa J. Review of oximes in the antidotal treatment of poisoning by organophosphorus nerve agents. J Toxicol Clin Toxicol 2002; 40: 803–16PubMedCrossRefGoogle Scholar
  188. 188.
    Marrs TC, Rice P, Vale JA. The role of oximes in the treatment of nerve agent poisoning in civilian casualties. J Toxicol Clin Toxicol 2003; 41: 453–4Google Scholar
  189. 189.
    Lieske CN, Clark JH, Maxwell DM, et al. Studies of the amplification of carbaryl toxicity by various oximes. Toxicol Lett 1992; 62: 127–37PubMedCrossRefGoogle Scholar
  190. 190.
    Lifshitz M, Rotenberg M, Sofer S, et al. Carbamate poisoning and oxime treatment in children: a clinical and laboratory study. Pediatrics 1994; 93: 652–5PubMedGoogle Scholar
  191. 191.
    Dawson A, Buckley N, Whyte J. What target pralidoxime concentration? J Toxicol Clin Toxicol 1997; 35: 227–8PubMedCrossRefGoogle Scholar
  192. 192.
    Mahieu P. Severe and prolonged poisoning by fenthion: significance of the determination of the anticholinesterase capacity of plasma. J Toxicol ClinToxicol 1982; 19: 425–32CrossRefGoogle Scholar
  193. 193.
    Eyer P. Pharmacokinetic aspects for the improvement of oxime therapy [abstract]. Przegl Lek 1995; 52: 202Google Scholar
  194. 194.
    Eyer P, Worek F, Thiermann H. Easy laboratory tests to follow the acetylcholinesterase status during oxime therapy in organophosphate poisoning. In: XIX International Congress of the European Association of Poison Centres and Clinical Toxicologists; 1999 Jun 22–25; Dublin: 110Google Scholar
  195. 195.
    Thiermann H, Mast U, Klimmek R, et al. Cholinesterase status, pharmacokinetics and laboratory findings during obidoxime therapy in organophosphate poisoned patients. Hum Exp Toxicol 1997; 16: 473–80PubMedCrossRefGoogle Scholar
  196. 196.
    Thiermann H, Szinicz L, Eyer F, et al. Modern strategies in therapy of organophosphate poisoning. Toxicol Lett 1999; 107: 232–9CrossRefGoogle Scholar
  197. 197.
    Worek F, Mast U, Kiderlen D, et al. Improved determination of acetylcholinesterase activity in human whole blood. Clin Chim Acta 1999; 288: 73–90PubMedCrossRefGoogle Scholar
  198. 198.
    Zilker T, Felgenhauer N, Hibler A, et al. Factors influencing the efficacy of obidoxime in organophosphate pesticides poisoning. Przeg Lek 1997; 54: 662–4Google Scholar
  199. 199.
    Riggs DS. The mathematical approach to physiological problems. Baltimore (MD): The William & Wilkins Company, 1963Google Scholar
  200. 200.
    Eyer P, Kiderlen D, Meischner V, et al. The current status of oximes in the treatment of OP poisoning: comparing two regimes. J Toxicol Clin Toxicol 2003; 41: 441–3Google Scholar

Copyright information

© Adis Data Information BV 2003

Authors and Affiliations

  1. 1.Walther-Straub-Institute of Pharmacology and ToxicologyLudwig-Maximilians-UniversityMunichGermany

Personalised recommendations